Fan AC, Deb-Basu D, Orban M, Gotlib J, Natkunam Y, O’Neill R, Padua R, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer D, Felsher DW. Nano-fluidic Proteomic Assay for Serial Quantitative Analysis of Oncoprotein Expression and Phosphorylation in Clinical Specimens. Nature Medicine, 2009 Apr 12 [Epub ahead of print]. [Pubmed Abstract]
Tran PT, Felsher DW. The current STATe of biomarkers to predict the response to anti-angiogenic therapies. Cancer Biol Ther. 2008 Dec;7(12):2004-6.
Felsher DW. Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphat Res Biol. 2008;6(3-4):149-54. Review. [Pubmed Abstract]
Arvanitis C, Bendapudi PK, Tseng JR, Gambhir SS, Felsher DW. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biol Ther. 2008 Dec;7(12):1947-51. [Pubmed Abstract]
Felsher DW. Tumor dormancy and oncogene addiction. APMIS. 2008 Jul-Aug;116(7-8):629-37. Review. [Pubmed Abstract]
Fan AC, Goldrick MM, Ho J, Liang Y, Bachireddy P, Felsher DW. A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Mol Cancer. 2008 Sep 30;7:74. [Pubmed Abstract]
Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res. 2008 Jul 1;68(13):5132-42. [Pubmed Abstract]
Beer S, Komatsubara K, Bellovin DI, Kurobe M, Sylvester K, Felsher DW. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS ONE. 2008 Jun 18;3(6):e2493. [Pubmed Abstract]
Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet. 2008 Jun 6;4(6):e1000090. [Pubmed Abstract]
Tran TP, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung ade nocarcinomas and lymphomas. PLoS ONE. 2008 May 7;3(5):e2125. [Pubmed Abstract]
Felsher DW. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 2008 May 1;68(9):3081-6. Review.[Pubmed Abstract]
Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15400-5. [Pubmed Abstract]
Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell. 2007 Sep;12(3):230-8. [Pubmed Abstract]
Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13028-33. [Pubmed Abstract]
Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 2007 Oct 1;110(7):2674-84. [Pubmed Abstract]
Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegue E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71. Epub 2006 Oct 20. [Pubmed Abstract]
Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol. 2006 Aug;16(4):313-7. Review. [Pubmed Abstract]
Felsher DW. Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle. 2006 Aug;5(16):1808-11. Review. [Pubmed Abstract]
Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsher D, Blacklow SC, Pear WS, Aster JC. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006 Aug 1;20(15):2096-109.
Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, Felsher DW.
MYC Can Induce DNA Breaks In vivo and In vitro Independent of Reactive Oxygen Species. Cancer Res. 2006 Jul 1;66(13):6598-6605. [Pubmed Abstract]
Deb-Basu D, Karlsson A, Li Q, Dang CV, Felsher DW. MYC Can Enforce Cell Cycle Transit From G(1) To S and G(2) To S, But Not Mitotic Cellular Division, Independent of p27-Mediated Inihibition of Cyclin E/CDK2. Cell Cycle. 2006 Jun 15;5(12). [Pubmed Abstract]
Deb-Basu D, Aleem E, Kaldis P, Felsher D. CDK2 Is Required By MYC To Induce Apoptosis. Cell Cycle. 2006 Jun 15;5(12). [Pubmed Abstract]
Kwon H, Ogle L, Benitez B, Bohuslav J, Montano M, Felsher DW, Greene WC. Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem. 2005 Oct 21;280(42):35713-22. Epub 2005 Aug 16. [Pubmed Abstract]
Sander S, Bullinger L, Karlsson A, Giuriato S, Hernandez-Boussard T, Felsher DW, Pollack JR. Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. Oncogene. 2005 Sep 8;24(40):6101-7. [Pubmed Abstract]
Arvanitis C, Felsher DW. Conditionally MYC: insights from novel transgenic models. Cancer Lett. 2005 Aug 26;226(2):95-9. Review. [Pubmed Abstract]
Beverly LJ, Felsher DW, Capobianco AJ. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res. 2005 Aug 15;65(16):7159-68. [Pubmed Abstract]
Shachaf CM, Felsher DW. Rehabilitation of cancer through oncogene inactivation. Trends Mol Med. 2005 Jul;11(7):316-21. Review. [Pubmed Abstract]
Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res. 2005 Jun 15;11(12):4278-81. Review. [Pubmed Abstract]
Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res. 2005 Jun 1;65(11):4471-4. Review. [Pubmed Abstract]
Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004 Oct 10. [Pubmed Abstract]
Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, Cardiff RD, Felsher DW. Developmental Context Determines Latency of MYC-Induced Tumorigenesis. PLoS Biol. 2004 Sep 28;2(11). [Pubmed Abstract]
Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14198-203. [Pubmed Abstract]
Yang Y, Contag CH, Felsher D, Shachaf CM, Cao Y, Herzenberg LA, Tung JW. The E47 transcription factor negatively regulates CD5 expression during thymocyte development. Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3898- 902.
Felsher, D. W. Reversibility of oncogene induced cancer. Current Opinion Genetics and Development. 14:37-42, 2004.
Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol. 2004 Feb;14(1):3-11. [PubMed Abstract]
Felsher DW. Related Articles, Links Oncogenes as therapeutic targets. Semin Cancer Biol. 2004 Feb;14(1):1.
Felsher DW, Bradon N. Pharmacological inactivation of MYC for the treatment of cancer. Drug News Perspect. 2003 Jul-Aug;16(6):370-4. Review. [PubMed Abstract ]
Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9974-9. [Full Text]
Giuriato S, Felsher DW. How cancers escape their oncogene habit. Cell Cycle. 2003 Jul-Aug;2(4):329-32. [PubMed Abstract]
Felsher DW. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer. 2003 May;3(5):375-80. Review. [PubMed Abstract]
Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 2003 Apr 1;101(7):2797-803. [PubMed Abstract]
Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002 Jul 5;297(5578):102-4. [Full Text]
Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol. 2001; 21(11):3789-806. [Full Text]
Felsher DW, Zetterberg A, Zhu J, Tlsty T, Bishop JM. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10544-8. [Full Text]
Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999 Aug;4(2):199-207. [PubMed Abstract]
Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4. [Full Text]
Search PubMed for all articles